|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
US20090301928A1
(en)
*
|
2008-06-05 |
2009-12-10 |
United Comb & Novelty Corporation |
Packaging For Lipped Containers
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
NZ603525A
(en)
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
CA2730930C
(en)
|
2008-07-16 |
2015-01-13 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
US7718662B1
(en)
*
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
|
WO2012003544A1
(en)
*
|
2010-07-09 |
2012-01-12 |
The Walter And Eliza Hall Institute Of Medical Research |
Protein kinase inhibitors and methods of treatment
|
|
MX336875B
(es)
*
|
2010-08-10 |
2016-02-04 |
Celgene Avilomics Res Inc |
Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
|
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP2635284B1
(en)
|
2010-11-01 |
2019-12-18 |
Celgene CAR LLC |
Heterocyclic compounds and uses thereof
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
ES2759615T3
(es)
|
2011-04-01 |
2020-05-11 |
Univ Utah Res Found |
Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
|
|
JP6147727B2
(ja)
*
|
2011-04-01 |
2017-06-14 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
WO2012158795A1
(en)
*
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
PL2710005T3
(pl)
*
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
|
ES2770550T3
(es)
*
|
2011-05-17 |
2020-07-02 |
Univ California |
Inhibidores de quinasa
|
|
MX2014000130A
(es)
*
|
2011-06-28 |
2014-05-01 |
Pharmacyclics Inc |
Procedimientos y composiciones para la inhibicion de resorcion osea.
|
|
JP2014520863A
(ja)
|
2011-07-13 |
2014-08-25 |
ファーマサイクリックス，インク． |
Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
|
|
EP3812387A1
(en)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
|
US9364476B2
(en)
|
2011-10-28 |
2016-06-14 |
Celgene Avilomics Research, Inc. |
Methods of treating a Bruton's Tyrosine Kinase disease or disorder
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
TW201336847A
(zh)
*
|
2012-02-07 |
2013-09-16 |
Taiho Pharmaceutical Co Ltd |
喹啉基吡咯并嘧啶化合物或其鹽
|
|
DK2722332T3
(en)
*
|
2012-02-23 |
2016-06-20 |
Taiho Pharmaceutical Co Ltd |
Quinolylpyrrolopyrimidylforbindelse with concentrated ring or salt thereof.
|
|
CA2866852C
(en)
|
2012-03-15 |
2020-12-29 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
|
BR112014022790B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
|
|
WO2013155347A1
(en)
|
2012-04-11 |
2013-10-17 |
Izumi Raquel |
Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
|
|
WO2013157021A1
(en)
|
2012-04-20 |
2013-10-24 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
JP6182593B2
(ja)
|
2012-04-20 |
2017-08-16 |
アドヴィーナス セラピューティクス リミテッド |
置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
|
|
WO2013177668A1
(en)
*
|
2012-05-31 |
2013-12-05 |
Pharmascience, Inc. |
Protein kinase inhibitors
|
|
KR20210033067A
(ko)
|
2012-06-04 |
2021-03-25 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
|
SI2892900T1
(en)
|
2012-09-10 |
2018-01-31 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
CA2887465A1
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
WO2014055928A2
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
|
CN103848810A
(zh)
|
2012-11-30 |
2014-06-11 |
北京赛林泰医药技术有限公司 |
鲁顿酪氨酸激酶抑制剂
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
MX2015009952A
(es)
|
2013-02-08 |
2015-10-05 |
Celgene Avilomics Res Inc |
Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
|
|
KR20150119401A
(ko)
*
|
2013-02-22 |
2015-10-23 |
다이호야쿠힌고교 가부시키가이샤 |
3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
CA2901510C
(en)
*
|
2013-03-15 |
2022-11-29 |
Janssen Pharmaceutica Nv |
Processes for preparing ibrutinib derivatives and intermediates thereof
|
|
JP6495886B2
(ja)
*
|
2013-03-15 |
2019-04-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｔｋ阻害剤としての複素環式芳香族化合物
|
|
KR20160061911A
(ko)
|
2013-04-08 |
2016-06-01 |
데니스 엠. 브라운 |
최적하 투여된 화학 화합물의 치료 효과
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CA2902686C
(en)
|
2013-04-25 |
2017-01-24 |
Beigene, Ltd. |
Fused heterocyclic compounds as protein kinase inhibitors
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
CN112472699A
(zh)
|
2013-07-26 |
2021-03-12 |
种族肿瘤学公司 |
改善比生群及衍生物的治疗益处的组合方法
|
|
JP6800750B2
(ja)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
固形腫瘍の処置方法
|
|
US9415050B2
(en)
|
2013-08-12 |
2016-08-16 |
Pharmacyclics Llc |
Methods for the treatment of HER2 amplified cancer
|
|
BR112016003247B1
(pt)
*
|
2013-08-22 |
2022-05-10 |
Taiho Pharmaceutical Co., Ltd |
Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
|
|
BR112016005199B1
(pt)
|
2013-08-23 |
2022-02-22 |
Neupharma, Inc |
Certos compostos químicos, composições, e métodos
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
BR112016006978A2
(pt)
|
2013-09-30 |
2017-08-01 |
Pharmacyclics Llc |
inibidores de tirosina quinase de bruton
|
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
|
RU2653504C2
(ru)
*
|
2013-12-13 |
2018-05-10 |
Ф. Хоффманн-Ля Рош Аг |
Ингибиторы тирозинкиназы брутона
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2015132799A2
(en)
|
2014-02-03 |
2015-09-11 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
|
CN112353806A
(zh)
|
2014-02-21 |
2021-02-12 |
普林斯匹亚生物制药公司 |
Btk抑制剂的盐和固体形式
|
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
|
EP3134418A4
(en)
|
2014-04-23 |
2018-01-03 |
The Research Foundation for The State University of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
|
CN105017256A
(zh)
*
|
2014-04-29 |
2015-11-04 |
浙江导明医药科技有限公司 |
多氟化合物作为布鲁顿酪氨酸激酶抑制剂
|
|
CN106458919B
(zh)
*
|
2014-05-13 |
2019-03-15 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
|
CN104086551B
(zh)
*
|
2014-06-06 |
2016-09-21 |
人福医药集团股份公司 |
化合物及其制备方法和用途
|
|
GB201410430D0
(en)
*
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
KR20170033358A
(ko)
|
2014-08-07 |
2017-03-24 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나아제 저해제의 신규한 제제
|
|
EP3179858B1
(en)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Forms and compositions of an erk inhibitor
|
|
WO2016050422A1
(en)
*
|
2014-10-01 |
2016-04-07 |
Ratiopharm Gmbh |
Acid addition salt of ibrutinib
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
EP3042903B1
(en)
|
2015-01-06 |
2019-08-14 |
Impetis Biosciences Ltd. |
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
|
|
MA41350A
(fr)
*
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
Synthèse d'un inhibiteur de la tyrosine kinase de bruton
|
|
US10266535B2
(en)
|
2015-01-21 |
2019-04-23 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Inhibitor of FLT3 kinase and use thereof
|
|
CN105859721B
(zh)
*
|
2015-01-22 |
2018-04-17 |
浙江京新药业股份有限公司 |
一种伊布鲁替尼的制备方法
|
|
JP6681922B2
(ja)
*
|
2015-02-12 |
2020-04-15 |
上▲海▼度▲徳▼医▲藥▼科技有限公司 |
イブルチニブの製造方法
|
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
WO2016141044A1
(en)
|
2015-03-04 |
2016-09-09 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Erbb4 inhibitors and methods of use thereof
|
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
|
CN106146508A
(zh)
*
|
2015-03-19 |
2016-11-23 |
浙江导明医药科技有限公司 |
优化的联合用药及其治疗癌症和自身免疫疾病的用途
|
|
CN106146516B
(zh)
*
|
2015-04-20 |
2019-02-15 |
北京睿创康泰医药研究院有限公司 |
依鲁替尼药物杂质的制备方法
|
|
UA124090C2
(uk)
*
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
US9394312B1
(en)
*
|
2015-06-14 |
2016-07-19 |
Mark Quang Nguyen |
Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
|
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
JP7337502B2
(ja)
|
2015-09-16 |
2023-09-04 |
ロクソ オンコロジー， インコーポレイテッド |
がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
|
|
CN114716381B
(zh)
*
|
2015-12-16 |
2025-03-11 |
洛克索肿瘤学股份有限公司 |
可用作激酶抑制剂的化合物
|
|
EA039213B1
(ru)
|
2015-12-24 |
2021-12-17 |
Такеда Фармасьютикал Компани Лимитед |
Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
|
|
RU2728827C2
(ru)
*
|
2016-01-05 |
2020-07-31 |
Цзянсу Хэнжуй Медицин Ко., Лтд. |
Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
|
|
MX2018008771A
(es)
*
|
2016-01-19 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Formulaciones/composiciones que comprenden un inhibidor de btk.
|
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
KR102699906B1
(ko)
*
|
2016-01-21 |
2024-08-29 |
즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 |
브루톤 티로신 키나제 억제제
|
|
CN106995446B
(zh)
*
|
2016-01-22 |
2021-07-02 |
山东新时代药业有限公司 |
布鲁顿酪氨酸激酶抑制剂制备方法
|
|
CN109071455B
(zh)
|
2016-03-11 |
2022-08-02 |
嘉兴和剂药业有限公司 |
用于调节布鲁顿酪氨酸激酶的化合物及方法
|
|
WO2017198049A1
(zh)
*
|
2016-05-16 |
2017-11-23 |
浙江予川医药科技有限公司 |
作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
|
|
CN115054586B
(zh)
|
2016-06-29 |
2024-08-02 |
普林斯匹亚生物制药公司 |
改性的释放制剂
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
WO2018035061A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2018033853A2
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
WO2018033135A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
|
IL292938A
(en)
|
2016-09-19 |
2022-07-01 |
Mei Pharma Inc |
Combined treatment
|
|
WO2018079310A1
(ja)
|
2016-10-31 |
2018-05-03 |
大鵬薬品工業株式会社 |
エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤
|
|
JOP20190113A1
(ar)
*
|
2016-11-18 |
2019-05-15 |
Biocad Joint Stock Co |
مثبطات بروتون تيروزين كيناز
|
|
CA3045339A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
|
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
CN109311883B
(zh)
*
|
2017-02-09 |
2021-03-19 |
合肥合源药业有限公司 |
Flt3激酶抑制剂或其盐的晶型及其制备方法
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
US11377449B2
(en)
|
2017-08-12 |
2022-07-05 |
Beigene, Ltd. |
BTK inhibitors with improved dual selectivity
|
|
PL3677266T3
(pl)
|
2017-09-01 |
2024-07-01 |
Taiho Pharmaceutical Co., Ltd. |
Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21
|
|
TW201922256A
(zh)
|
2017-10-27 |
2019-06-16 |
中國大陸商浙江導明醫藥科技有限公司 |
治療淋巴樣惡性疾病之方法
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
CN108191871B
(zh)
*
|
2018-01-02 |
2020-02-18 |
成都倍特药业有限公司 |
新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
|
|
KR20210003780A
(ko)
|
2018-04-05 |
2021-01-12 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Axl 키나제 억제제 및 그의 용도
|
|
JP2021521170A
(ja)
|
2018-04-13 |
2021-08-26 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
|
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
CN109134472B
(zh)
*
|
2018-09-20 |
2020-02-11 |
浙江理工大学 |
一种3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-4-胺的合成工艺
|
|
CN110964016B
(zh)
*
|
2018-09-29 |
2021-05-28 |
南京药捷安康生物科技有限公司 |
氨基降茨烷衍生物及其制备方法与应用
|
|
CN109369654A
(zh)
*
|
2018-11-20 |
2019-02-22 |
山东大学 |
1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
|
|
US12351571B2
(en)
|
2018-12-19 |
2025-07-08 |
Array Biopharma Inc. |
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
|
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药（上海）有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
|
KR20260008165A
(ko)
|
2019-02-12 |
2026-01-15 |
스미토모 파마 아메리카, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
|
CN113544130B
(zh)
|
2019-05-31 |
2024-01-09 |
西藏海思科制药有限公司 |
一种btk抑制剂环衍生物及其制备方法和药学上的应用
|
|
US20220249491A1
(en)
|
2019-06-10 |
2022-08-11 |
Beigene Switzerland Gmbh |
Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
|
|
CN110606848A
(zh)
*
|
2019-08-27 |
2019-12-24 |
药雅科技(上海)有限公司 |
一种5-氮杂吲哚衍生物Bruton′s酪氨酸激酶抑制剂及其制备方法与用途
|
|
US20210106584A1
(en)
|
2019-10-14 |
2021-04-15 |
Principia Biopharma Inc. |
Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
CN115038700B
(zh)
|
2019-11-08 |
2025-07-25 |
内尔维亚诺医疗科学公司 |
偕二取代的杂环化合物及其作为idh抑制剂的用途
|
|
BR112022014058A2
(pt)
|
2020-01-20 |
2022-09-13 |
Genzyme Corp |
Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
|
|
US11814390B2
(en)
|
2020-01-22 |
2023-11-14 |
Principia Biopharma Inc. |
Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
|
CN113943294A
(zh)
*
|
2020-07-15 |
2022-01-18 |
成都海博为药业有限公司 |
一种作为btk抑制剂的化合物及其制备方法与用途
|
|
WO2022111447A1
(zh)
*
|
2020-11-25 |
2022-06-02 |
四川海思科制药有限公司 |
一种btk降解剂的制备方法
|
|
AU2021398051A1
(en)
|
2020-12-10 |
2023-07-27 |
Principia Biopharma Inc. |
Crystal form of tolebrutinib, preparation method therefor and use thereof
|
|
CN113004246B
(zh)
*
|
2021-02-22 |
2022-02-01 |
广西医科大学 |
1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
CN120302975A
(zh)
|
2022-10-31 |
2025-07-11 |
住友制药美国公司 |
治疗骨髓增生性肿瘤的pim1抑制剂
|